View all Events
Event Health

Precision Oncology in the Era of Health Care Reform Improving Outcomes, Sustaining Innovation, and Increasing Value

Thursday April 2016

Vice President Biden’s “cancer moonshot” and America’s ongoing debate over oncology-drug affordability have captured national attention. As patients, advocates, and families do battle with cancer, our medical and biotechnology community makes great strides in using patients’ precise biology to better target tumors. Delivering innovative treatments to patients safely, affordably, and effectively requires public policy that rises to the sophistication of our best science. Please join us on Capitol Hill to discuss new frameworks for clinical-data sharing, conditional-drug approvals, and value-based pricing that can help deliver better outcomes to patients and more value to America’s health care system.

10:00 - 10:15 AM Registration & Seating
10:15 - 10:25 AM Keynote Address:
Tom Coburn, Project FDA Advisor, Manhattan Institute
10:25 - 11:30 AM Advancing Effective and Affordable Precision Oncology
Moderator: Paul Howard, Director, Health Policy, Manhattan Institute
Amy Abernethy, Chief Medical Officer, Flatiron Health
Matt Shaulis, Regional President, Pfizer Oncology North America
Elizabeth Thompson, President and CEO, C-Change
Mark Trusheim, Visiting Scientist, MIT Sloan
11:30 - 12:00 PM Q&A
12:00 PM Lunch